AnaptysBio stock rises after positive rheumatoid arthritis trial data By Investing.com
Update: 2025-10-29
Description
AnaptysBio's experimental drug, rosnilimab, shows promising results in a Phase two B clinical trial for rheumatoid arthritis. The drug, designed to target and deplete specific T cells, improved symptoms in over 400 patients, regardless of previous treatments. The benefits lasted for at least three months after treatment stopped. Rosnilimab also reduced certain immune cells by over 90% and showed continued improvement in disease activity, remission rates, and response levels. With positive safety data and deep, sustained responses, rosnilimab could offer a new treatment option for patients who have tried multiple other therapies.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
